Head to Head Comparison: Twist Bioscience (TWST) & Its Competitors

Twist Bioscience (NASDAQ: TWST) is one of 111 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Twist Bioscience to similar businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Valuation and Earnings

This table compares Twist Bioscience and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Twist Bioscience $25.43 million -$71.23 million -0.94
Twist Bioscience Competitors $1.00 billion $89.63 million -4.25

Twist Bioscience’s peers have higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

48.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.1% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares Twist Bioscience and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Twist Bioscience N/A N/A N/A
Twist Bioscience Competitors -5,015.13% -60.99% -25.62%

Analyst Ratings

This is a summary of current ratings and recommmendations for Twist Bioscience and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Twist Bioscience 0 1 2 0 2.67
Twist Bioscience Competitors 736 2494 5717 230 2.59

Twist Bioscience currently has a consensus price target of $25.99, indicating a potential upside of 7.89%. As a group, “Biological products, except diagnostic” companies have a potential upside of 50.47%. Given Twist Bioscience’s peers higher probable upside, analysts clearly believe Twist Bioscience has less favorable growth aspects than its peers.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company was founded in 2013 and is headquartered in San Francisco, California.

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply